Literature DB >> 18667507

Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo.

Shuji Sato1, Eloisa Yuste, William A Lauer, Eun Hyuk Chang, Jennifer S Morgan, Jacqueline G Bixby, Jeffrey D Lifson, Ronald C Desrosiers, Welkin E Johnson.   

Abstract

Here, we describe the evolution of antigenic escape variants in a rhesus macaque that developed unusually high neutralizing antibody titers to SIVmac239. By 42 weeks postinfection, 50% neutralization of SIVmac239 was achieved with plasma dilutions of 1:1,000. Testing of purified immunoglobulin confirmed that the neutralizing activity was antibody mediated. Despite the potency of the neutralizing antibody response, the animal displayed a typical viral load profile and progressed to terminal AIDS with a normal time course. Viral envelope sequences from week 16 and week 42 plasma contained an excess of nonsynonymous substitutions, predominantly in V1 and V4, including individual sites with ratios of nonsynonymous to synonymous substitution rates (dN/dS) highly suggestive of strong positive selection. Recombinant viruses encoding envelope sequences isolated from these time points remained resistant to neutralization by all longitudinal plasma samples, revealing the failure of the animal to mount secondary responses to the escaped variants. Substitutions at two sites with significant dN/dS values, one in V1 and one in V4, were independently sufficient to confer nearly complete resistance to neutralization. Substitutions at three additional sites, one in V4 and two in gp41, conferred moderate to high levels of resistance when tested individually. All the amino acid changes leading to escape resulted from single nucleotide substitutions. The observation that antigenic escape resulted from individual, single amino acid replacements at sites well separated in current structural models of Env indicates that the virus can utilize multiple independent pathways to rapidly achieve similar levels of resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667507      PMCID: PMC2546989          DOI: 10.1128/JVI.00871-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

Review 1.  Viral persistence: HIV's strategies of immune system evasion.

Authors:  Welkin E Johnson; Ronald C Desrosiers
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

2.  Accuracy and power of bayes prediction of amino acid sites under positive selection.

Authors:  Maria Anisimova; Joseph P Bielawski; Ziheng Yang
Journal:  Mol Biol Evol       Date:  2002-06       Impact factor: 16.240

3.  Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus.

Authors:  Welkin E Johnson; Jeffrey D Lifson; Sabine M Lang; R Paul Johnson; Ronald C Desrosiers
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.

Authors:  K S Cole; M Alvarez; D H Elliott; H Lam; E Martin; T Chau; K Micken; J L Rowles; J E Clements; M Murphey-Corb; R C Montelaro; J E Robinson
Journal:  Virology       Date:  2001-11-10       Impact factor: 3.616

5.  Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.

Authors:  Eloisa Yuste; Hannah B Sanford; Jill Carmody; Jacqueline Bixby; Susan Little; Michael B Zwick; Tom Greenough; Dennis R Burton; Douglas D Richman; Ronald C Desrosiers; Welkin E Johnson
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

Review 6.  Immune evasion strategies of the primate lentiviruses.

Authors:  D T Evans; R C Desrosiers
Journal:  Immunol Rev       Date:  2001-10       Impact factor: 12.988

7.  A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope.

Authors:  Welkin E Johnson; Jennifer Morgan; Julie Reitter; Bridget A Puffer; Susan Czajak; Robert W Doms; Ronald C Desrosiers
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  Analysis of simian immunodeficiency virus sequence variation in tissues of rhesus macaques with simian AIDS.

Authors:  T Kodama; K Mori; T Kawahara; D J Ringler; R C Desrosiers
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

10.  Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.

Authors:  D P Burns; C Collignon; R C Desrosiers
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more
  20 in total

1.  Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.

Authors:  Thomas S Postler; José M Martinez-Navio; Eloísa Yuste; Ronald C Desrosiers
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.

Authors:  Wendy W Yeh; Laura M Brassard; Caroline A Miller; Aravind Basavapathruni; Jinrong Zhang; Srinivas S Rao; Gary J Nabel; John R Mascola; Norman L Letvin; Michael S Seaman
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

3.  Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys.

Authors:  Aravind Basavapathruni; Wendy W Yeh; Rory T Coffey; James B Whitney; Peter T Hraber; Ayush Giri; Bette T Korber; Srinivas S Rao; Gary J Nabel; John R Mascola; Michael S Seaman; Norman L Letvin
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

4.  Balancing reversion of cytotoxic T-lymphocyte and neutralizing antibody escape mutations within human immunodeficiency virus type 1 Env upon transmission.

Authors:  Viv Peut; Shahan Campbell; Adriana Gaeguta; Rob J Center; Kim Wilson; Sheilajen Alcantara; Caroline S Fernandez; Damian F J Purcell; Stephen J Kent
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

5.  Analysis of SIVmac Envelope-Specific Antibodies Selected Through Phage Display.

Authors:  Sergio Ita; Mayara R Agostinho; Katherine Sullivan; Seung Yub Han; Rana Akleh; Welkin E Johnson; Ismael Ben F Fofana
Journal:  AIDS Res Hum Retroviruses       Date:  2017-02-16       Impact factor: 2.205

6.  Immunoglobulin VH gene diversity and somatic hypermutation during SIV infection of rhesus macaques.

Authors:  Kejun Guo; Kalani Halemano; Kimberly Schmitt; Miki Katuwal; Yaqiong Wang; Michael S Harper; Karl J Heilman; Takeo Kuwata; Edward B Stephens; Mario L Santiago
Journal:  Immunogenetics       Date:  2015-05-21       Impact factor: 2.846

7.  Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.

Authors:  Wendy W Yeh; Ishita Rahman; Peter Hraber; Rory T Coffey; Daiva Nevidomskyte; Ayush Giri; Mohammed Asmal; Svetlana Miljkovic; Marcus Daniels; James B Whitney; Brandon F Keele; Beatrice H Hahn; Bette T Korber; George M Shaw; Michael S Seaman; Norman L Letvin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

8.  Mamu-B*17+ Rhesus Macaques Vaccinated with env, vif, and nef Manifest Early Control of SIVmac239 Replication.

Authors:  Mauricio A Martins; Damien C Tully; Núria Pedreño-Lopez; Benjamin von Bredow; Matthias G Pauthner; Young C Shin; Maoli Yuan; Noemia S Lima; David J Bean; Lucas Gonzalez-Nieto; Aline Domingues; Martin J Gutman; Helen S Maxwell; Diogo M Magnani; Michael J Ricciardi; Varian K Bailey; John D Altman; Dennis R Burton; Keisuke Ejima; David B Allison; David T Evans; Eva G Rakasz; Christopher L Parks; Myrna C Bonaldo; Saverio Capuano; Jeffrey D Lifson; Ronald C Desrosiers; Todd M Allen; David I Watkins
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

9.  Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies.

Authors:  Eloìsa Yuste; Jacqueline Bixby; Jeffrey Lifson; Shuji Sato; Welkin Johnson; Ronald Desrosiers
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

Review 10.  Specificity of the autologous neutralizing antibody response.

Authors:  Penny L Moore; Elin S Gray; Lynn Morris
Journal:  Curr Opin HIV AIDS       Date:  2009-09       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.